<span item_type="fundamental" item_id="aa8dcea1428031251bf776111aa9682b" counter_id="ST/US/NRXPW" env="prod"></span><span item_type="announcement" item_id="516478741585925121" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -0.34.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not generated any revenue during the three months ended March 31, 2025, or the year ended December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1719406/000143774925017252/nrxp20250331c_10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The company reported a net loss of $5.5 million for the three months ended March 31, 2025, compared to a net loss of $6.5 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1719406/000143774925017252/nrxp20250331c_10q.htm"></span></li><li><strong>Operating Expenses</strong>: Total operating expenses decreased from $5.998 million in 2024 to $3.847 million in 2025, primarily due to reduced research and development and general administrative expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1719406/000143774925017252/nrxp20250331c_10q.htm"></span></li><li><strong>Research and Development</strong>: Expenses were $0.8 million in 2025, down from $1.7 million in 2024, reflecting the conclusion of the phase 2 study related to NRX-101 and cash conservation efforts.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1719406/000143774925017252/nrxp20250331c_10q.htm"></span></li><li><strong>General and Administrative</strong>: Expenses were $2.9 million in 2025, down from $4.3 million in 2024, due to decreases in insurance, stock-based compensation, consultant fees, and employee expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1719406/000143774925017252/nrxp20250331c_10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: The company used $3.5 million in cash for operating activities in the three months ended March 31, 2025, compared to $3.7 million in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1719406/000143774925017252/nrxp20250331c_10q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: Financing activities provided $7.6 million in cash during the three months ended March 31, 2025, primarily from proceeds of $3.3 million from issuance of common stock and warrants related to the RD Offering and $5.0 million from the Anson Notes.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1719406/000143774925017252/nrxp20250331c_10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Convertible Notes Payable</strong>: The carrying value of Anson Notes was $8.397 million as of March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1719406/000143774925017252/nrxp20250331c_10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to submit two lead drug candidates for FDA approval in the second quarter of 2025, with anticipated FDA decision dates by year-end 2025. The company aims to transform from a pre-revenue biotechnology company to a revenue-generating enterprise through its subsidiary HOPE Therapeutics, which will focus on interventional psychiatric treatment.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1719406/000143774925017252/nrxp20250331c_10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is negotiating acquisitions of precision psychiatry centers to form the foundation for HOPE Therapeutics, aiming to create a national network offering interventional psychiatry to treat suicidal depression and PTSD. The company has executed a term sheet for a strategic investment of $2.5 million to support the expansion of HOPE clinics.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1719406/000143774925017252/nrxp20250331c_10q.htm"></span></li></ul>

NRX Pharmaceuticals - CW22 | 10-Q: FY2025 Q1 EPS: USD -0.34